Institutional Investors Lead Shift in Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Sentiment

May 21, 2018 - By Louis Casey

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Logo

Sentiment for Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

Progenics Pharmaceuticals Inc (NASDAQ:PGNX) institutional sentiment increased to 1.22 in Q4 2017. Its up 0.11, from 1.11 in 2017Q3. The ratio has increased, as 62 investment professionals increased or started new holdings, while 51 sold and decreased positions in Progenics Pharmaceuticals Inc. The investment professionals in our partner’s database now have: 56.89 million shares, down from 58.90 million shares in 2017Q3. Also, the number of investment professionals holding Progenics Pharmaceuticals Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 40 Increased: 40 New Position: 22.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $556.95 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

The stock increased 4.50% or $0.325 during the last trading session, reaching $7.555. About 570,486 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has declined 32.66% since May 21, 2017 and is downtrending. It has underperformed by 44.21% the S&P500.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on August, 8. They expect $-0.19 EPS, up 20.83 % or $0.05 from last year’s $-0.24 per share. After $-0.19 actual EPS reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Ardsley Advisory Partners holds 1.32% of its portfolio in Progenics Pharmaceuticals, Inc. for 1.83 million shares. Phocas Financial Corp. owns 1.44 million shares or 0.72% of their US portfolio. Moreover, Rice Hall James & Associates Llc has 0.32% invested in the company for 1.38 million shares. The New York-based Sio Capital Management Llc has invested 0.28% in the stock. Pinnacle Associates Ltd, a New York-based fund reported 2.21 million shares.

More recent Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) news were published by: Seekingalpha.com which released: “Progenics Earnings: Get Ready For A Massive Move” on May 10, 2018. Also Globenewswire.com published the news titled: “Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update” on May 09, 2018. Seekingalpha.com‘s news article titled: “Progenics Pharmaceuticals’ (PGNX) CEO Mark Baker on Q1 2018 Results – Earnings Call Transcript” with publication date: May 09, 2018 was also an interesting one.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.